Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650239 | 0.79 | — | — | |
| SCHEMBL19866261 | 0.77 | ADRA2A (0.35) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL20336329 | 0.76 | KIF11 (0.61) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL80368 | 0.76 | KIF11 (0.43) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL23860299 | 0.73 | KIF11 (0.45) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL20261725 | 0.73 | KIF11 (0.45) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL6105719 | 0.73 | KIF11 (0.49) | KIF11GABRB3GABRA1GABRG2 | |
| SCHEMBL14655026 | 0.73 | KIF11 (0.49) | KIF11GABRB3GABRA1GABRG2ADRA2A | |
| SCHEMBL3938311 | 0.71 | — | — | |
| SCHEMBL5275595 | 0.70 | MAOB (0.39) | KIF11GABRB3GABRA1GABRG2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475283-B1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | claimed |
| EP-3475280-B1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-08 | — | — | EP | claimed |
| US-10457686-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | claimed |
| US-20190127386-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | claimed |
| EP-3475283-A1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | claimed |
| EP-3475280-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-01 | — | — | EP | claimed |
| WO-2017220516-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | claimed |
| WO-2017220544-A1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | claimed |
| US-7084285-B2 | Photoaffinity-labeled sphingomyelin analogs and processes thereof | DAISO CO., LTD. (JP) | 2006-08-01 | — | — | US | claimed |
| US-20050182265-A1 | Photoaffinity-labeled sphingomyelin analogs and processes thereof | DAISO CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| EP-3475283-B1 | NOVEL[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3475280-B1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-10457686-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | KIF11 2747/4885GABRB3 2680/4885GABRA1 3085/4885 |
| US-20050182265-A1 | Photoaffinity-labeled sphingomyelin analogs and processes thereof | SGMS1, SGMS2, SMPD1 | KIF11 2322/4885GABRB3 3689/4885GABRA1 3720/4885 |
| US-20190127383-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | KIF11 1885/4885GABRB3 1919/4885GABRA1 1851/4885 |
| US-10457684-B2 | [1,2,3]triazolo[4,5-d]pyrimidine derivatives | TYMS, DPYD, TYMP | KIF11 2053/4885GABRB3 2454/4885GABRA1 1743/4885 |
| US-20190127386-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, TBXA2R | KIF11 1885/4885GABRB3 1919/4885GABRA1 1851/4885 |
| US-10457686-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | TYMS, DPYD, TYMP | KIF11 2053/4885GABRB3 2454/4885GABRA1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.